Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus

References

• Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–2121.
   PubMed Web of Science ®Google Scholar
• Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. Int J Rheum Dis. 2020;23:465–471.
   PubMed Web of Science ®Google Scholar
• Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol. 2014;10:212–228.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958–967. • International task force formulated recommendations on implementing a T2T approach in SLE.
   PubMed Web of Science ®Google Scholar
• Murphy G, Isenberg DA. New therapies for systemic lupus erythematosus - past imperfect, future tense. Nat Rev Rheumatol. 2019;15:403–412.
   PubMed Web of Science ®Google Scholar
• Liu Z, and Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med. 2012;18:871–882.
   PubMed Web of Science ®Google Scholar
• Gupta S, Kaplan ML. Bite of the wolf: innate immune responses propagate autoimmunity in lupus. J Clin Invest. 2021;131:e144918.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–233.
   PubMed Web of Science ®Google Scholar
• Mysler EF, Spindler AJ, Brunetta P, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis results from a randomized, double-blind, Phase III study. Arthritis Rheum. 2013;65:2368–2379.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Wallance DJ, Gordon C, et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017;69:362–375.
   PubMed Web of Science ®Google Scholar
• Shen L, Liu X, Sun C, et al. Rituximab therapy for lupus nephritis: a meta‑analysis. World Academy Sci J. 2021;3:48.
   Google Scholar
• Alshaiki F, Obaid E, Almuallim A, et al. Outcome of rituximab therapy in refractory lupus; a meta-analysis. Eur J Rheumatol. 2018;5:118–126.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736–745.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the joint european league against rheumatism and European renal association–European dialysis and transplant association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713–723.
   PubMed Web of Science ®Google Scholar
• Gordon C, Amissah-Arthur MB, Gayed M, et al. The British society for rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57:e1–e45.
   PubMed Web of Science ®Google Scholar
• Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2021 Oct;6:annrheumdis-2021-220920. Epub ahead of print. PMID: 34615636.
   Google Scholar
• Nakayamada S, Iwata S, Tanaka Y. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. Int J Rheum Dis. 2015;18:208–218.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Yoshikawa M, et al. Peripheral immunophenotyping identifies three subgroups based on T cell heterogeneity in lupus patients. Arthritis Rheumatol. 2017;69:2029–2037.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kubo S, Miyagawa I, et al. Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases. Semin Arthritis Rheum. 2019;48:1146–1150.
   PubMed Web of Science ®Google Scholar
• Navarra S, Guzmán RM, Gallacher AE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–731.
   PubMed Web of Science ®Google Scholar
• Zhang F, Bae S, Tanaka Y, et al. A pivotal Phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77:355–363.
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117–1128.
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020;382:211–221.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Maeshima K, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis. 2012;71:i70–i74.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2012;368:161–170.
   Web of Science ®Google Scholar
• Tanaka Y, Luo Y, O’Shea JJ, et al. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022 Jan;5: 1–13. Online ahead of print. •• This is a review that discusses the therapeutic application of mechanism-based JAK inhibitors.
   Google Scholar
• Tanaka Y. The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases? Rheumatology. 2019;58(Supplement_1):i1–i3.
   PubMedGoogle Scholar
• Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology. 2019;58:953–962.
   PubMed Web of Science ®Google Scholar
• Gadina M, Chisolm DA, Philips RL, et al. Translating JAKs to Jakinibs. J Immunol. 2020;204:2011–2020.
   PubMed Web of Science ®Google Scholar
• Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415–1421.
   PubMed Web of Science ®Google Scholar
• Liongue C, Ward AC. Evolution of the JAK-STAT pathway. Jakstat. 2013;2:e22756.
   PubMedGoogle Scholar
• Nash P, Smolen JS, Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80:71–87.
   PubMed Web of Science ®Google Scholar
• Schwartz D, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2016;16:843–862.
   Web of Science ®Google Scholar
• Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18:374–384.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Suzuki M, Nakamura H, et al. Tofacitinib study investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 2011;63:1150–1158.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, et al. ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559–570.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78:1320–1332.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or Adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788–1800.
   PubMed Web of Science ®Google Scholar
• Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or Adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848–858.
   PubMed Web of Science ®Google Scholar
• Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511–1521.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–2311.
   PubMed Web of Science ®Google Scholar
• Ma X, Nakayamada S, Kubo S, et al. Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors. Ann Rheum Dis. 2018;77:1354–1361.
   PubMed Web of Science ®Google Scholar
• Lee S, Nakayamada S, Kubo S, et al. Interleukin-23 drives expansion of Thelper 17 cells through epigenetic regulation by signal transducer and activators of transcription 3 in lupus patients. Rheumatology (Oxford). 2020;59:3058–3069.
   PubMed Web of Science ®Google Scholar
• Nakayamada S, Tanaka Y. Clinical relevance of T follicular helper cells in systemic lupus erythematosus. Expert Rev Clin Immunol. 2021;17:1143–1150. • This is a review that discusses the involvement of lymphocytes in SLE.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Tanaka Y, et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front Immunol. 2018;9:1510.
   PubMed Web of Science ®Google Scholar
• Kubo S, Yamaoka K, Tanaka Y, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73:2192–2198.
   PubMed Web of Science ®Google Scholar
• Maeshima K, Yamaoka K, Tanaka Y, et al. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 2012;64:1790–1798.
   PubMed Web of Science ®Google Scholar
• Ikeda K, Hayakawa K, Fujishiro M, et al. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation. BMC Immunol. 2017;18:41.
   PubMed Web of Science ®Google Scholar
• Furumoto Y, Smith CK, Blanco L, et al. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheum. 2017;69:148–160.
   PubMed Web of Science ®Google Scholar
• Ripoll E, de Ramon L, Draibe BJ, et al. JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther. 2016;18:134.
   PubMed Web of Science ®Google Scholar
• Hasni SA, Gupta S, Davis M, et al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. 2021;12:3391. •• This study demonstrated the safety and tolerability of tofacitinib in SLE patients, stratified by the STAT4 risk alleles.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2019;392:222–231. •• This study demonstrated the efficacy and safety of baricitinib in SLE patients.
   Google Scholar
• Baker M, Chaichian Y, Genovese M, et al. Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy. RMD Open. 2020;6:e001490.
   PubMed Web of Science ®Google Scholar
• Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. [2019 Jul 24];11(502):eaaw1736.
   PubMed Web of Science ®Google Scholar
• Danese S, and Peyrin-Biroulet L. Selective tyrosine kinase 2 inhibition for treatment of inflammatory bowel disease: new hope on the rise. Inflamm Bowel Dis. 2021;27(12):2023–2030.
   Web of Science ®Google Scholar
• Mease P, Deodhar A, van der Heijde D, et al. Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol. 2020;72(suppl 10):L03
   Google Scholar
• Hunter DJ. Uncertainty in the era of precision medicine. N Engl J Med. 2016;375(8):711–713.
   PubMed Web of Science ®Google Scholar
• Hagberg N, Joelsson M, Leonard D, et al. The STAT4 SLE risk allele rs7574865[T] is associated with increased IL-12-induced IFN-γ production in T cells from patients with SLE. Ann Rheum Dis. 2018;77:1070.
   PubMed Web of Science ®Google Scholar
• Bechman K, Subesinghe S, Nortonet S, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology. 2019;58:1755–1766.
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13:234–243.
   PubMed Web of Science ®Google Scholar
• Setyawan J, Mu F, Yarur A, et al. Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases. Clin Ther. 2021;43:1392–1407.
   PubMed Web of Science ®Google Scholar
• Setyawan J, Azimi N, Strand V, et al. Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019. Drug Saf. 2021;44:889–897.
   PubMed Web of Science ®Google Scholar